A new prostaglandin E1 analogue (TFC-612) prevents a decrease in motor nerve conduction velocity in streptozocin-diabetic rats.

Abstract

A new prostaglandin E1 analogue (TFC-612) was orally given to streptozocin-diabetic rats for 4 weeks after the induction of diabetes and its effects on motor nerve conduction velocity were studied. The compound significantly prevented a decrease of the velocity but did not reverse abnormal sorbitol and myo-inositol contents of the sciatic nerve. The results suggest that TFC-612 has a potent effect on diabetic nerve dysfunction via other mechanism than the correction of sorbitol and myo-inositol metabolisms and could be a potential compound for therapy of diabetic polyneuropathy.

• Authors: H Yasuda, M Sonobe, I Hatanaka, M Yamashita, Y Miyamoto, M Terada, M Amenomori, R Kikkawa, Y Shigeta, Y Motoyama
• Journal: Biochemical and biophysical research communications (Biochem Biophys Res Commun) Vol. 150 Issue 1 Pg. 225-30 (Jan 15 1988) ISSN: 0006-291X [Print] United States
• PMID: 3276309 (Publication Type: Journal Article)

Chemical References

• Insulin
• Prostaglandins E, Synthetic
• Inositol
• Sorbitol
• TFC 612
• Alprostadil

Topics

• Alprostadil (analogs & derivatives, therapeutic use)
• Animals
• Diabetes Mellitus, Experimental (drug therapy, physiopathology)
• Diabetic Neuropathies (drug therapy, physiopathology)
• Inositol (metabolism)
• Insulin (therapeutic use)
• Male
• Motor Neurons (physiology)
• Neural Conduction
• Prostaglandins E, Synthetic
• Rats
• Rats, Inbred Strains
• Sciatic Nerve (physiopathology)
• Sorbitol (metabolism)